IgG2 anti-Galalpha1-3Gal does not induce porcine aortic endothelial cell accommodation in vitro.
BACKGROUND
Xenografts that have been protected from hyperacute rejection (HAR) are termed accommodated if they are not then rejected despite the presence of xenoantibody. It has been proposed that IgG may confer resistance to complement dependent cytotoxicity (CDC), a conventional in vitro marker of accommodation. We hypothesized that noncytotoxic IgG2 anti-Galalpha1-3Gal was responsible for this effect.


RESULTS
We purified IgG anti-Galalpha1-3Gal from pooled human normal immunoglobulin and three sera, by elution from protein G and Galalpha1-3Gal-R immunoadsorbents. The eluates were IgM free and > or =95% IgG2. They bound to Galalpha1-3Gal, porcine aortic endothelial cells (PAEC) and lymphocytes. It was not possible to block IgM binding to PAEC or lymphocytes using IgG anti-Galalpha1-3Gal (200 microg/ml). The eluates were noncytotoxic in micro-CDC assays. To investigate accommodation, PAEC were cultured with subsaturating doses of the four IgG eluates for up to 144 hr. Resistance of nontrypsinized PAEC to CDC by human serum was measured in a cell viability assay. PAEC were not rendered resistant to CDC in any of the experiments. To investigate the possibility that accommodation might be induced by non-Galalpha1-3Gal IgG, the experiments were repeated using HNIg, again with no protection demonstrated.


CONCLUSIONS
Using primary PAEC monolayers, we were unable to induce resistance to CDC with human normal immunoglobulin and its IgG2 anti-Gabeta1-3Gal subset. This contradicts previous experiments using trypsinized, immortalized cells. Although resistance to CDC is not an ideal marker of accommodation, the detrimental effects of IgG make it unlikely that it will become a useful clinical means of inducing accommodation.
McKane
W
W
The Brent Laboratory, St Mary's Hospital, London, UK.
Lee
J
J
Preston
R
R
van Dam
M
M
Cairns
T
T
Taube
D
D
D000208:Acute Disease; D000818:Animals; D000906:Antibodies / Q000494:pharmacology; D017690:Cell Transplantation / Q000502:physiology; D003602:Cytotoxicity, Immunologic; D004187:Disaccharides / Q000276:immunology*; D004730:Endothelium, Vascular / Q000166:cytology*; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007074:Immunoglobulin G / Q000737:chemistry; D013552:Swine; D014183:Transplantation, Heterologous / Q000276:immunology
D000906:Antibodies; D004187:Disaccharides; D007074:Immunoglobulin G; C055075:galactosyl-(1-3)galactose